Enanta announces CHMP grants positive opinions of AbbVie's VIEKIRAXTM
Enanta announced the European Committee for Medicinal Products for Human Use of the EMA has granted positive opinions for AbbVie’s investigational, all-oral, interferon-free treatment of VIEKIRAX™. AbbVie anticipates a final decision in the first quarter of 2015. November 21, 2014